Loading data for ABUS — first visit, this takes a few seconds.
Arbutus Biopharma Corporation
5.12 +0.00 (0.00%)
5.11 -0.20%
- Capitalización de mercado
- $1.01B
- Volumen
- 1.85M
- Próxima fecha de resultados
- Nov 16, 2026
Arbutus Biopharma Corporation (ABUS): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $179.1M | n/a | +10054.54% |
| EPS | -$0.04 | -$0.01 | -500.00% |
Métricas
- Precio de compra
- 3.68
- Ingresos (TTM)
- 182M
- Beneficio neto (TTM)
- 153M
- 0.62
- 0.79
- 6.48
- -30.98
- P/B (TTM)
- 3.91
- P/S (TTM)
- 5.58
- Fecha de resultados
- Nov 16, 2026
- Precio de venta
- 5.13
- Volumen
- 1,850,049
- Volumen medio (20D)
- 3,097,398
- Abierto
- 5.17
- Anterior Cerrar
- 5.12
- Rango del día
- 5.11 - 5.17
- Rango de 52 semanas
- 3.50 - 5.45
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Arbutus Biopharma Corporation
Ver perfil →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Industria Biotechnology
Sector Healthcare
IPO Fecha Jul 26, 2007
Empleados 19
Bolsa de Valores NasdaqGS
Símbolo bursátil ABUS
Sitio web https://www.arbutusbio.com